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Haematopoietic stem
cell transplantationfrontline evolved to CML-AP or CML-BP.
Results: With a median follow-up of 38 months (range: 2e190 months), the cumulative inci-
dence of progression at 1 and 3 years was 3% (confidence interval [CI] 95%: 1e5%) and 7% (CI
95%: 4e11%), respectively. We observed a large predominance of lymphoid-BP (70%) over
myeloid-BP (30%) with imatinib in frontline therapy. Sixteen patients underwent haemato-
poietic stem cell transplantation, and eight were treated with a tyrosine kinase inhibitor after
transplant. Only the transplanted patients are alive. The 5-year overall survival rate of children
with CML-AP/BP is 44%, with no statistical difference between the lymphoid-BP and
myeloid-BP outcome.
Conclusion: Children evolving to AP or BP under treatment with imatinib have a very poor
prognosis with an overall survival under 50%, much worse than children with advanced phase
at diagnosis.
ª 2020 Elsevier Ltd. All rights reserved.1. Introduction
Chronic myeloid leukaemia (CML) is rare in children,
accounting for 2e3% of childhood leukaemias [1], with
an average annual incidence of 0.6e1.0 cases per million
in children younger than 15 years [2]. At diagnosis,
approximately 95% of paediatric patients are in chronic
phase (CML-CP), similar to the frequency in adults [3].
In the absence of treatment, CML progresses from
CML-CP to accelerated phase (CML-AP) or blastic
phase (CML-BP) [4]. The frequency of progression to
CML-AP or CML-BP is remarkably reduced by tyro-
sine kinase inhibitor (TKI) treatment, currently esti-
mated to be in the range of 1e1.5% per year [5] versus
more than 20% yearly in the pre-TKI era [6]. In adults,
CML-BP occurring under TKI treatment expresses a
predominantly myeloid phenotype (60e80%) [7].
Despite guidelines for the management of CML-BP in
adult patients, their outcome is poor, with an overall
survival (OS) at 12 months from 20% before TKI era to
50% after the introduction of TKI [8]. Imatinib was
introduced for the treatment of children with CML in
the 2000s and is still the most prescribed first-line ther-
apy for CML-CP even if the second-generation TKI
(2G-TKIs) have been recently approved in this age
group [9,10]. Here, we aimed to describe the character-
istics and outcome of CML-AP and CML-BP occurring
under treatment with imatinib in children with CML.2. Materials and methods
Patients were identified from the I-CML-Ped Study
(www.clinicaltrials.gov #NCT01281735), a database of
patients from 0 to 18 years with CML from 37 centres
in 14 countries. The I-CML-Ped Study was set up to
assess epidemiology, management and outcome of
CML in children and adolescents and recorded the
data retrospectively from 2000 until 2010, then
prospectively from 2011. This study was approved bythe institutional review board of the University
Hospital of Poitiers, in accordance with the
declaration of Helsinski.
A total of 445 patients were enrolled from 2001 to
January 2016. At diagnosis, 376 patients were in CML-
CP according to the European LeukaemiaNet (ELN)
criteria [11], and 339 received upfront imatinib treat-
ment. Among the 339 patients in CML-CP with imati-
nib frontline, 19 patients evolved from CML-CP to
CML-AP or to CML-BP and represent the study
cohort named as AP/BP cohort (Supplemental Figure).
The median follow-up of the AP/BP cohort was 38
months (range: 2e190). Patient characteristics are pro-
vided in Table 1. The median age at diagnosis of AP/BP
cohort was 13.2 years (range: 4.5e16.8) with a M/F sex
ratio of 2.8. Progression to CML-AP or CML-BP is a
time-dependent variable. Therefore, to compare the
characteristics at diagnosis of the AP/BP cohort to a
control cohort of patients who did not progress with
imatinib frontline, we took into consideration only the
patients who had a follow-up above 58 months, which is
the maximum delay of CML-BP onset of the AP/BP
cohort. We also excluded the transplanted patients from
the control cohort because haematopoietic stem cell
transplantation (HSCT) could change the prognosis
(Supplemental Figure). Although, it is important to
mention that no death was recorded in the whole cohort
of patients who did not progress and have a follow-up
>58 months, inclusive of both transplanted and non-
transplanted patients. Overall, the control cohort in-
cludes 92 patients. The median follow-up of the control
cohort was 94 months (range: 58.1e168.3 months).
The Sokal score was determined using the formula
for patients aged under 45 years [12]. The diagnosis of
CML was assessed by cytogenetic analysis or in case of
failure by fluorescence in situ hybridisation (FISH) [13].
BCR-ABL1 transcript level in the blood was determined
by using quantitative reverse transcriptase-polymerase
chain reaction as reported previously and was
expressed according to the international scale [14]. The
Table 1
Patient characteristics at the time of diagnosis in chronic phase.
Characteristics N Z 92
Control
patients
N
missing
N Z 19
AP/BP
patients
N
missing
p N Z 2
AP
N Z 12
Lymphoid-BP
N Z 5
Myeloid-BP
p
Gender, no. (%) >0.05 >0.05
Female 42 (46) 5 (26) 1 2 (17) 2 (40)
Male 50 (54) 14 (74) 1 10 (83) 3 (60)
Age at diagnosis, y
Median (range) 11.4 (1.0e17.4) 13.2 (4.5e16.8) >0.05 14.3 (13.8e14.8) 12.4 (6e15.4) 11.8 (4.5e16.8) >0.05
< 4 (%) 8 (9) 0 (0) 0 (0) 0 (0) 0 (0)
4e9 (%) 22 (24) 4 (21) 0 (0) 3 (25) 1 (20)
10e14 (%) 43 (47) 11 (58) 2 (100) 7 (58) 2 (40)
 15 (%) 19 (21) 4 (21) 0 (0) 2 (17) 2 (40)
Lansky performance (%) 6 3 NA >0.05
100 52 (60) 10 (63) 0 (0) 7 (70) 3 (75)
90 20 (23) 4 (25) 1 (50) 2 (20) 1 (25)
80 10 (12) 2 (12) 1 (50) 1 (10) 0 (0)
<80 4 (5) 0 (0) 0 (0) 0 (0) 0 (0)
Splenomegaly, no. (%) 65 (71) 1 18 (95) 0.0388 2 (100) 11 (92) 5 (100) >0.05
Spleen size, cm 7
Median (range) 6 (0e24) 12 (0e25) 0.0003 >0.05
 10 55 (65) 5 (26) 0 (0) 3 (25) 2 (40)
>10 30 (35) 14 (74) 2 (100) 9 (75) 3 (60)
Hepatomegaly, no. (%) 31 (34) 1 9 (47) >0.05 1 (50) 5 (42) 3 (60) >0.05
Sokal risk score
for patients. (%)
10 >0.05 >0.05
Low (<0.8) 17 (21) 1 (5) 0 (0) 1 (8) 0 (0)
Intermediate (0.8e1.2) 24 (29) 4 (21) 0 (0) 2 (17) 2 (40)
High (>1.2) 41 (50) 14 (74) 2 (100) 9 (75) 3 (60)
ELTS risk score. (%) 10 0.0003 >0.05
Low (<0.8) 54 (66) 5 (26) 0 (0) 5 (42) 0 (0)
Intermediate (0.8e1.2) 20 (24) 5 (26) 0 (0) 2 (17) 3 (60)
High (>1.2) 8 (10) 9 (48) 2 (100) 5 (42) 2 (40)
Median WBC count
(range) x109/L
253 (5e810) 360 (70e637) 0.0329 411 371 225 >0.05
Median haemoglobin
(range), g/L
94 (40e170) 89 (68e138) >0.05 111 91 86 >0.05
Median platelet count
(range) x109/L
504 (51e4220) 428 (25e976) 0.0107 480 309 472 >0.05
BCR-ABL1 transcripts 11 2 NA NA
p210 81 17 1 12 4
b2a2 32 4 0 2 2
b3a2 43 4 0 3 1
b2a2/b3a2 6 2 1 1 0
Unspecified 0 7 0 6 1
AP, accelerated phase; BP, blastic phase; Y, years; no, number; WBC, white blood cell; NA, not applicable.
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cording to the ELN criteria [11]. CML-AP was defined
by blasts in blood or bone marrow (BM) between 15 and
29% or blasts cells plus promyelocytes in blood or
BM > 30% with blasts cells < 30%, basophils in
blood > 20%, persistent thrombocytopenia
(<100  109/l) unrelated to therapy and cytogenetic
evidence of clonal evolution. CML-BP was defined by
the presence of at least 30% of blasts cells in blood or
BM or evidence of extramedullary disease [11]. The
myeloid or lymphoid immunophenotype of CML-BP
was determined by flow cytometry [15]. BCR-ABL1 ki-
nase domain (KD) mutation analysis was performed as
previously reported in case of suboptimal response or
treatment failure. Differences in baseline characteristicsbetween AP/BP cohort and the control cohort were
tested using the Fisher’s exact test for categorical data or
the Wilcoxon rank sum test for continuous variables.
OS was estimated using the KaplaneMeier method [16].
To account for competing events, incidence of progres-
sion along time was estimated by the cumulative inci-
dence function with the use of Fine and Gray models.
Competitive events were deaths from causes other than
progression. Analyses were performed using the SAS v
9.3 (SAS Institute).
3. Results
In the I-CML-Ped Study database, the cumulative
incidence of progression at 1 and 3 years was 3%
Table 2
Summary table of chronic phase and CML-AP or CML-BP.
Patients Chronic phase Accelerated phase or blastic phase
Age
(y),
sex,
First-line
treatment
Stop
TKI
Interval***
(m)
Type Treatment of
CML-AP/CML-BP
ABL1
KD
mutations
CR
before
HSCT
MR
before
HSCT
%
or
patibility
Preparative
regimen
Outcome
1 15,
M
Hydroxyurea,
imatinib
Yes* 12.3 Lymphoid-
BP
CNSþ
Dasatinib for 2 weeks
(stop for neutropenia),
then
corticosteroid þ rituximab þ daunorubicin/
vincristine/
cyclophosphamide/L-asparaginase þ TIT þ
nilotinib
P-loop
L248V
Complete 0 elated cord
d, 6/6
TBI/
cyclophosphamide
Dead, sepsis from
Cryptococcus laurenti
2 12,
M
Hydroxyurea,
imatinib
þ TIT
No 24.9 Myeloid-BP ELAM02: Induction,
then
consolidation 1, then
half-consolidation
3 þ nilotinib
F317L Complete 3.7 elated
or, BM 9/
Busulfan/
cyclophosphamide/
ATG
Alive, still nilotinib
post-allograft (5 years
post-transplant)
3 14,
M
Hydroxyurea,
cytarabine,
interferon,
imatinib
Yes** 31
(lymphoid-
BP
40
(myeloid-
BP)
Lymphoid-
BP
CNS þ then
myeloid-BP
Lymphoid-BP:
dexamethasone,
HYPERCVAD
(cyclophoshamide/
vincristine/doxorubicin
/dexamethasone)
methotrexate
þ HD-cytarabine þ
dasatinib. 12 TIT,
Radiotherapy
18 Gy, 2 IT,
Myeloid-BP: azacytidine,
LD-cytarabine þ nilotinib
No
mutation
Complete 0.17 elated cord
d (double),
Cyclophosphamide/
fludarabine/TBI
Dead, relapse,
dasatinib
post-allograft, then
interferon
4 11,
F
Imatinib No 9.2 Myeloid-BP ELAM02: Induction,
then
consolidation 1 þ dasatinib,
then HD-cytarabine
þgemtuzumab ozogamicin
ND ND ND
splantation
No transplantation Dead, no remission
5 17,
M
Imatinib No 21 Myeloid-BP Fludarabine-HD- cytarabine
eliposomal daunorubicin- IT
of cytarabine then,
fludarabine -
HD-cytarabine and
dasatinib
No
mutation
Complete 0.14 elated
or
10/10
Busulfan/
cyclophosphamide/
ATG
Alive (4 years post-
transplant)
(continued on next page)
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Table 2 (continued )
Patients Chronic phase Accelerated phase or blastic phase
Age
(y),
sex,
First-line
treatment
Stop
TKI
Interval***
(m)
Type Treatment of
CML-AP/CML-BP
ABL1
KD
mutations
CR
before
HSCT
MR
before
HSCT
%
Donor
Compatibility
Preparative
regimen
Outcome
6 14,
F
Hydroxyurea,
imatinib
Yes* 11.7 CML-AP Switch to dasatinib No
mutation
Minor 5.2 Genoid, BM Cyclophosphamide/
busulfan
Alive (4 years post-
transplant)
7 14,
M
Imatinib Yes* 8.5 Lymphoid-
BP
Dasatinib T315I,
E255K
Failure >1 Unrelated
donor, PB 10/
10
MD Dead, relapse,
nilotinib,
then ponatinib
post-allograft
8 9, M Imatinib No 4.1 Lymphoid-
BP
Dasatinib alone, then
induction according
to EsPhALL with
dasatinib
ND Complete 0.13 Unrelated
donor BM 10/
10
TBI/etoposide/
cyclophosphamide
Alive (4 years post-
transplant), dasatinib
(6 months) post-
allograft
9 9, M Imatinib No 5.4 Lymphoid-
BP
Dasatinib, then ALL11
protocol with dasatinib
T315I Complete 0.016 Genoid, BM TBI/etoposide/
cyclophosphamide
Alive, ponatinib
post-allograft.
Relapse:
ALL
protocol þ ponatinib.
Reject of second
transplant. Waiting for
a third transplant.
10 6, M Hydroxyurea,
imatinib
No 31.9 Lymphoid-
BP
Induction FRALLE
B1þdasatinib/
EsPhALL phase 1b,
bloc HR1 with dasatinib
No
mutation
Complete 0.22 Unrelated
donor, 10/10
TBI/etoposide/
ATG
Alive (2 years post-
transplant)
11 13,
F
Imatinib No 5 CML-AP,
lymphoid-BP
CML-AP: dasatinib
Lymphoid-BP:
ALL-BFM2009:
2xvincristine,
2xdaunorubicin, 1x cyclophosphamide,
prednisone
E255K,
PLOOP
ND 5.14 Genoid, BM TBI/etoposide Alive (2 years post-
transplant), dasatinib
post-allograft
12 14,
M
Hydroxyurea,
imatinib
No 19.1 Lymphoid-
BP
ALL-BFM2009 þ
ALLIC-BFM2009
with dasatinib
ND Complete 0 Genoid, BM MD Alive, dasatinib post-
allograft
13 12,
M
Hydroxyurea,
imatinib,
mitoxantrone
Yes** 58.4 Lymphoid-
BP
ST JUDE TOTAL
XV for ALL with
dasatinib
ND Partial 89 Genoid, BM MD Alive
14 11,
F
Hydroxyurea,
imatinib,
Yes** 16.3 Lymphoid-
BP
EsPhALL with imatinib ND ND ND No
transplantation
No transplantation Dead, progressive
disease, aspergillosis
15 16,
M
Imatinib No 17.8 Myeloid-BP 3 blocks of AML-BFM 2004 þ dasatinib ND ND ND Haploidentical
(mother), PB
MD Dead, progressive
disease and infection
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D. Meyran et al. / European Journal of Cancer 137 (2020) 224e234 229(confidence interval [CI] 95%: 1e5%) and 7% (CI 95%:
4e11%), respectively. Baseline characteristics of the AP/
BP cohort compared with the control cohort of 92 pa-
tients who did not progress with imatinib frontline are
presented in Table 1. Notably, patients in the AP/BP
group had significantly more aggressive clinical and
biological features with larger splenomegaly, higher
white blood cells count and lower platelet count. Only
EUTOS long-term survival (ELTS) score at CML-CP
diagnosis was significantly discriminant to predict pro-
gression with nine (48%) of the 19 AP/BP patients who
were high-risk compared with 8 (10%) in the control
cohort. Eight patients had a BCR-ABL1 fusion identi-
fied by FISH only. The other AP/BP patients had a
karyotype showing the classical translocation t(9; 22)
(q34; q11), except for one who had a variant trans-
location t(1; 9;22) (q12; q34; q11).
Eleven of the 19 patients (58%) received hydroxyurea
before the start of TKI. Imatinib was the first-line TKI
for all patients. The dose was 260 mg/m2 for 12 patients
and 300e340 mg/m2 for seven. Three patients received a
concomitant additional treatment: triple intrathecal in-
jection (n Z 1) for a retinal leukostasis, mitoxantrone
(n Z 1) to reduce the leucocytes count and cytarabine/
interferon (n Z 1) for haemorrhagic retinopathy (Table
2). Because of non-achievement of cytogenetic and/or
molecular responses, the dose of imatinib was increased
in six patients (from 260 to 300 mg/m2 or from 300 to
400e600 mg/m2), whereas eight were switched to dasa-
tinib (60e80 mg/m2). By comparison, among the 320
patients treated with imatinib frontline who did not
progress, 71 (22%) were switched to a 2G-TKI because
of poor response. Furthermore, three from the five pa-
tients of the AP/BP cohort who initially had a good
response discontinued imatinib for toxicity (n Z 2) or
inadequate compliance (n Z 1). Before the occurrence
of CML-AP/CML-BP, six patients (31%) obtained a
complete cytogenic response (CCyR) after a median
time of 12 months (range: 6e29), and only two (11%)
achieved a major molecular response (MMR) at 18
months (Supplemental Table 1).
The median duration of TKI before the occurrence of
CML-AP or CML-BP was 11.4 months (range: 3e56.6).
Seven patients (37%) discontinued TKI for a median
duration of 40 days (range: 7e130), for intolerance
(n Z 4) and non-compliance (n Z 3). Among the four
patients who discontinued imatinib for intolerance,
imatinib was resumed in three of them at the same dose
(n Z 1) or at a lower dose (n Z 2). The other patient
who was initially treated with a reduced dosage of
imatinib was finally switched to dasatanib. The muta-
tional status of the BCR-ABL1 kinase domain was only
evaluated for 12 patients when CML-AP or CML-BP
was diagnosed. Six of the 12 patients monitored (50%)
acquired KD mutations (Table 2). In the study cohort,
four patients quickly evolved to CML-AP after a me-
dian of 8.7 months (range: 3.2e18.1) from the start of
D. Meyran et al. / European Journal of Cancer 137 (2020) 224e234230imatinib. For one patient, CML-AP was exclusively
defined by clonal evolution with the emergence of
monosomy 7. CML-AP evolved rapidly to CML-BP for
two patients, after a median of 3.5 months (range:
1.8e5.3). Overall, 17 patients evolved to CML-BP,
including two after CML-AP after a median of 12.3
months from diagnosis (range: 3e58).
Twelve (70%) of the 17 patients evolved towards
lymphoid CML-BP whilst five (30%) evolved towards
myeloid CML-BP, after a median of 9.8 months (range:
3e56.6) and 17.7 months (range: 9.2e24.6) from the
start of imatinib, respectively. At the time of CML-AP
or CML-BP, 10 of 11 patients monitored (90%) acquired
additional cytogenetic abnormalities (Supplemental
Table 2).
CML-AP was treated by increasing the dose of imati-
nib from 300 to 500e600 mg/day for two of the four pa-
tients in CML-AP, whereas the others were switched to
dasatinib. Sixteen of 17 patients in CML-BP were treated
according to acute myeloid leukaemia (AML) or acute
lymphoblastic leukaemia protocols, combined with ima-
tinib or 2G-TKI. Only one patient, patient 7, with
lymphoid CML-BP was treated with dasatinib alone
before HSCT (Table 2). Three patients died from pro-
gressive disease before scheduledHSCT after a median of
12.5 months (range: 6.5e19.2) from CML-AP/CML-BP
diagnosis. Overall, 16 patients underwent HSCT. The
median interval from CML-AP/CML-BP diagnosis to
HSCTwas 5months (range: 1.2e8.5). At transplant, nine
of the remaining 16 patients (56%) had achieved CCyR
and four (25%)MMR (Supplemental Table 1). Details of
the HSCT procedures are given in Table 2. At first
assessment post-HSCT, 10 patients (63%) were in CCyR
and nine (56%) in MMR. Eight received a 2G-TKI post-
transplant. After HSCT, five patients died, three from
progressive disease and two from transplant-related
events. Eleven patients are still alive; 10 are in MMR,
but one had a lymphoid CML-BP relapse 26months after
transplant. Five-year OS was 44% (Fig. 1A), with no
statistical difference between lymphoid-BPOS (29%) and
myeloid-BP OS (40%) (Fig. 1B).4. Discussion
This is the first study to assess the incidence and the
outcome of CML-AP and CML-BP in children treated
with imatinib. Imatinib still remains the main frontline
therapy in children because there is more experience
with its efficacy and its toxicity than with the other TKIs
[17e19]. Only few studies have evaluated the rate of
progression to CML-AP or CML-BP in a population-
based setting. A recent report in adults showed a rate
of cumulative incidence of progression of 4.3% at 2
years [20]. We observed a quite similar proportion in
children with cumulative incidence of progression at 1and 3 years at 3% (CI 95%: 1e5%) and 7% (CI 95%:
4e11%), respectively.
Many studies have previously reported that children
in CP have clinical presentations with more aggressive
features than adults [21e23]. However, scoring systems
in CML based on clinical and biological characteristics
of the disease at diagnosis, such as Sokal, Hasford and
EUTOS, have been developed within an adult setting. In
children with CML, only the ELTS score at diagnosis
demonstrates better differentiation of progression-free
survival [24]. In our study, we used both the Sokal
young score and ELTS score to define the risk groups of
the patients. The vast majority (74%) of the AP/BP
cohort and half of the control patients were allocated to
the high-risk group according to the Sokal young score,
whereas the ELTS score identified a lower proportion of
high-risk children in the control cohort (10%) compared
with the proportion in the AP/BP cohort (48%). Sokal
risk score that classifies most of the children with CML-
CP in high-risk group at diagnosis is therefore less
discriminating for predicting progression than ELTS
risk score. Until a new specific score incorporating
clinical, biological and molecular features is developed
in this age group to better predict progression, patients
with high ELTS risk score must be closely monitored.
Early cytogenetic and molecular responses are re-
ported to be the best predictors of good outcome [11].
These two parameters were clearly not satisfactory in
our cohort. Non-adherence is one of the most common
reasons for suboptimal response and treatment failure in
patients with CML treated with TKI [25]. Indeed,
adolescence is a well-known challenge to compliance in
paediatric patients with chronic diseases [26,27]. In our
study, the proportion of discontinuation of this paedi-
atric AP/BP cohort is approximately the same as that
reported in previous studies for adults with CML
treated by oral TKI (15e30%) [28]. However, the pro-
portion of patients who discontinued TKI for inade-
quate compliance and experienced CML progression
remains difficult to assess because it relies on patients’
declaration. At the onset of CML-AP or CML-BP, 50%
of the patients who were monitored acquired KD mu-
tations including T315I mutation. KD mutations T315I
and G250E are associated with imatinib failure, which
can be overcome by switching treatment to a third or
fourth generation TKI [29]. However, in paediatrics, the
therapeutic options are limited because ponatinib is still
not approved in children. Only few cases of young pa-
tients treated by ponatinib have been reported in the
literature, with no safe dose having been determined in
children [30,31]. For suboptimal responses or failure,
patients have been either treated with an increased dose
of imatinib or switched to a 2G-TKI. Recently, a ther-
apeutic algorithm based on paediatric haematologists’
experience has been proposed to treat children in CML-
CP once failure or suboptimal response has been
detected [32]. Probably with this new algorithm, some of
D. Meyran et al. / European Journal of Cancer 137 (2020) 224e234 231our patients would have been switched earlier to a 2G-
KI. However, it should be taken into account that the I-
CML study is an international database and access to
certain expensive molecules like the 2G-TKI could be
more difficult in some of the countries participating in
this study.
In adult cohorts, a predominance of myeloid immu-
nophenotype of CML-BP (60e80%) was observed
[7,33]. In contrast to adult patients with CML, we
observed predominantly lymphoid-BP (70%) in children
with upfront imatinib treatment. In another report from
the I-CML-Study, we have also observed a predomi-
nance of lymphoid phenotype of de novo advanced
phases of childhood CML [34]. The median time to the
onset of the myeloid-BP was longer than that of
lymphoid-BP, 17.7 months (range: 9.2e24.6) and 9.8
months (range: 3e56.6) respectively. Similarly, in an
adult cohort, the median time from first diagnosis toFig. 1. Outcome of CML-AP/CML-BP. Overall survival since the onse
for the overall population and (B) by subtype (CML-AP, lymphoid-BP
chronic myeloid leukaemia.myeloid-BP was also longer than that of lymphoid-BP,
39 months (range: 0e307) and 24 months
(range:0e161), respectively [35]. The median follow-up
of 38 months is sufficiently long to limit a follow-up
dependent bias.
While children with de novo advanced phases have a
favourable outcome with 5-year OS rates at 94% and
74% for patients diagnosed in CML-AP and CML-BP
respectively [34], the survival is poorer, less than 50%,
when the transformation occurs from CML-CP to
CML-AP or CML-BP while on TKI therapy. A similar
outcome is observed in adults treated after progression
from CML-CP with a median survival rate between 6
and 37 months and less than 12 months for patients with
CML-AP and CML-BP, respectively [7,33]. Like adult
cohorts [33], our data suggest that allo-HSCT may
represent the best chance of long-term remission or cure
in CML-BP. The current National Comprehensivet of imatinib was analysed using KaplaneMeier methodology (A)
and myeloid-BP). AP, accelerated phase; BP, blastic phase; CML,
D. Meyran et al. / European Journal of Cancer 137 (2020) 224e234232Cancer Network guidelines suggest that patients who
progress to CML-BP should receive an allo-HSCT
within 3e6 months from diagnosis [8,36]. However,
experience in children with CML in advanced stages is
very limited because of the small number of cases.
5. Conclusion
In a paediatric setting, the cumulative incidence of
progression of CML-CP with upfront imatinib treat-
ment at 1 and 3 years is 3% and 7%, respectively, with a
predominance of lymphoid progression. While children
with de novo advanced phases have a favourable
outcome, the 5-year OS of progression to CML-AP or
CML-BP in paediatric patients is poor, less than 50%,
with no significant difference in outcome by immuno-
phenotypic subtype. Bearing in mind the small number
of paediatric patients with CML, allo-HSCT remains
the best therapeutic option for the young patients in
CML-AP or CML-BP who progressed under treatment
with imatinib.
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